Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients

NCT04427098 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

301

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Enoxaparin 40 Mg/0.4 mL Injectable Solution
DRUG: Enoxaparin

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna